Literature DB >> 9882361

X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus.

G C Faulkner1, S R Burrows, R Khanna, D J Moss, A G Bird, D H Crawford.   

Abstract

Epstein-Barr virus (EBV) infects both B lymphocytes and squamous epithelial cells in vitro, but the cell type(s) required to establish primary and persistent infection in vivo has not been definitively elucidated. The aim of this study was to investigate a group of individuals who lack mature B lymphocytes due to the rare heritable disorder X-linked agammaglobulinemia in order to determine the role of the B cell in the infection process. The results show that none of these individuals harbored EBV in their blood or throat washings. Furthermore, no EBV-specific memory cytotoxic T lymphocytes were found, suggesting that they had not undergone infection in the past. In contrast, 50% of individuals were found to carry human herpesvirus 6, showing that they are infectible by another lymphotropic herpesvirus. These results add weight to the theory that B lymphocytes, and not oropharyngeal epithelial cells, may be required for primary infection with EBV.

Entities:  

Mesh:

Year:  1999        PMID: 9882361      PMCID: PMC103980          DOI: 10.1128/JVI.73.2.1555-1564.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Replication of EBV in epithelial cells during infectious mononucleosis.

Authors:  S M Lemon; L M Hutt; J E Shaw; J L Li; J S Pagano
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

2.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

Authors:  K Nilsson; G Klein; W Henle; G Henle
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

3.  Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis.

Authors:  A B Rickinson; J E Jarvis; D H Crawford; M A Epstein
Journal:  Int J Cancer       Date:  1974-12-15       Impact factor: 7.396

4.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis.

Authors:  P Gerber; S Lucas; M Nonoyama; E Perlin; L I Goldstein
Journal:  Lancet       Date:  1972-11-11       Impact factor: 79.321

6.  Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

Authors:  A Wang; S D Lu; D F Mark
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

7.  Epstein-Barr virus replication in oropharyngeal epithelial cells.

Authors:  J W Sixbey; J G Nedrud; N Raab-Traub; R A Hanes; J S Pagano
Journal:  N Engl J Med       Date:  1984-05-10       Impact factor: 91.245

8.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

9.  Replication of Epstein-Barr virus in human epithelial cells infected in vitro.

Authors:  J W Sixbey; E H Vesterinen; J G Nedrud; N Raab-Traub; L A Walton; J S Pagano
Journal:  Nature       Date:  1983 Dec 1-7       Impact factor: 49.962

10.  Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia.

Authors:  K Sandvej; L Krenács; S J Hamilton-Dutoit; J L Rindum; J J Pindborg; G Pallesen
Journal:  Histopathology       Date:  1992-05       Impact factor: 5.087

View more
  28 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

3.  The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells.

Authors:  Georg W Bornkamm; Uta Behrends; Josef Mautner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

4.  Virus and cell RNAs expressed during Epstein-Barr virus replication.

Authors:  Jing Yuan; Ellen Cahir-McFarland; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 5.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

7.  Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

Authors:  John G Kosowicz; Jaeyeun Lee; Brandon Peiffer; Zufeng Guo; Jianmeng Chen; Gangling Liao; S Diane Hayward; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?

Authors:  Richard F Ambinder
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

9.  An in vitro system for studying murid herpesvirus-4 latency and reactivation.

Authors:  Janet S May; Neil J Bennett; Philip G Stevenson
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

10.  Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions.

Authors:  Debbie E Wright; Susanna Colaco; Camilo Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-07-22       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.